These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 24829953)
21. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. Teo KY; Ng WY; Lee SY; Cheung CM Drugs; 2016 Jul; 76(11):1119-33. PubMed ID: 27364753 [TBL] [Abstract][Full Text] [Related]
22. [Intravitreal ranibizumab injections for the treatment of choroidal neovascularization complicating high myopia]. Ouhadj O; Bouarfa A; Akel S; Mendil L; Nebab A; Nouri MT J Fr Ophtalmol; 2010 Nov; 33(9):649-54. PubMed ID: 21047702 [TBL] [Abstract][Full Text] [Related]
23. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Wu TT; Kung YH Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318 [TBL] [Abstract][Full Text] [Related]
31. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Lai TY Retina; 2012 Sep; 32(8):1443-5. PubMed ID: 22922844 [No Abstract] [Full Text] [Related]
33. Myopic choroidal neovascularization: natural course and treatment. Ohno-Matsui K; Yoshida T Curr Opin Ophthalmol; 2004 Jun; 15(3):197-202. PubMed ID: 15118506 [TBL] [Abstract][Full Text] [Related]
34. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP Retina; 2010; 30(10):1609-15. PubMed ID: 20856171 [TBL] [Abstract][Full Text] [Related]
35. Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization. Moon BG; Cho AR; Lee J; Kim YJ; Lee JY; Kim JG; Yoon YH Ophthalmologica; 2017; 237(3):128-138. PubMed ID: 28278507 [TBL] [Abstract][Full Text] [Related]
37. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Fujii GY; Humayun MS; Pieramici DJ; Schachat AP; Au Eong KG; de Juan E Am J Ophthalmol; 2001 Jan; 131(1):90-100. PubMed ID: 11162983 [TBL] [Abstract][Full Text] [Related]
38. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Yang HS; Kim JG; Kim JT; Joe SG Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429 [TBL] [Abstract][Full Text] [Related]
39. [Surgery for choroidal subfoveal neovascularization in patients with severe myopia. Retrospective analysis of 17 patients]. Hera R; Mouillon M; Gonzalvez B; Millet JY; Romanet JP J Fr Ophtalmol; 2001 Sep; 24(7):716-23. PubMed ID: 11591911 [TBL] [Abstract][Full Text] [Related]
40. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Hayashi K; Ohno-Matsui K; Yoshida T; Kobayashi K; Kojima A; Shimada N; Yasuzumi K; Futagami S; Tokoro T; Mochizuki M Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):13-9. PubMed ID: 15290153 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]